Drug Profile
RVX 100
Alternative Names: RVX-100Latest Information Update: 17 May 2010
Price :
$50
*
At a glance
- Originator Revogenex
- Class Irritable bowel syndrome therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Irritable bowel syndrome
Most Recent Events
- 17 May 2010 Suspended - Phase-II for Irritable bowel syndrome in USA (unspecified route)
- 20 Apr 2010 Phase-II clinical trials in Irritable bowel syndrome in USA (unspecified route)
- 25 Feb 2010 Investigation in Irritable bowel syndrome in USA (unspecified route)